Low plasma levels of the soluble receptor for advanced glycation end products in HIV-infected patients with subclinical carotid atherosclerosis receiving combined antiretroviral therapy

Su Jin Jeong, Chang Oh Kim, Young Goo Song, Ji hyeon Baek, Sun Bean Kim, Sung Joon Jin, Nam Su Ku, Sang Hoon Han, Jun Yong Choi, Hyun Chul Lee, June Myung Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: Combined antiretroviral therapy (cART) has significantly improved the survival rate and quality of life for HIV-infected subjects, but it contributes to the development of metabolic complications including coronary artery disease (CAD). Recent studies have reported that high plasma levels of the soluble receptor for advanced glycation end products (sRAGE) were associated with a lower incidence of CAD in non-HIV infected patients. However, there has been no report of an association of sRAGE and subclinical carotid atherosclerosis in HIV-infected patients receiving cART. Methods: We examined the association of circulating sRAGE in HIV-infected patients with carotid intima-media thickness (IMT) and other metabolic variables. We prospectively enrolled 76 HIV-infected patients receiving cART for ≥6 months. Results: sRAGE had a significantly negative correlation with body mass index (r= -0.324, p= 0.005), waist-to-hip ratio (r= -0.335, p= 0.003), systolic blood pressure (BP) (r= -0.359, p= 0.002), diastolic BP (r= -0.343, p= 0.004), total cholesterol (r= -0.240, p= 0.037), low-density lipoprotein-cholesterol (r= -0.284, p= 0.024), log(homeostasis model assessment of insulin resistance [HOMA-IR]) (r= -0.380, p= 0.002) and carotid IMT including max-IMT and mean-IMT (r= -0.358, p= 0.001 and r= -0.329, p= 0.004, respectively). By the use of multiple stepwise regression analyses, systolic BP (p= 0.001) and log[HOMA-IR] (p= 0.001) remained significant independently. Conclusions: These results suggest that sRAGE may have a protective effect against subclinical atherosclerosis by preventing inflammatory responses mediated by the activation of cell surface RAGE in HIV-infected patients receiving cART.

Original languageEnglish
Pages (from-to)778-783
Number of pages6
JournalAtherosclerosis
Volume219
Issue number2
DOIs
Publication statusPublished - 2011 Dec 1

Fingerprint

Carotid Artery Diseases
HIV
Blood Pressure
Carotid Intima-Media Thickness
Insulin Resistance
Coronary Artery Disease
Homeostasis
Therapeutics
Waist-Hip Ratio
LDL Cholesterol
Advanced Glycosylation End Product-Specific Receptor
Atherosclerosis
Body Mass Index
Survival Rate
Cholesterol
Regression Analysis
Quality of Life
Incidence

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Jeong, Su Jin ; Kim, Chang Oh ; Song, Young Goo ; Baek, Ji hyeon ; Kim, Sun Bean ; Jin, Sung Joon ; Ku, Nam Su ; Han, Sang Hoon ; Choi, Jun Yong ; Lee, Hyun Chul ; Kim, June Myung. / Low plasma levels of the soluble receptor for advanced glycation end products in HIV-infected patients with subclinical carotid atherosclerosis receiving combined antiretroviral therapy. In: Atherosclerosis. 2011 ; Vol. 219, No. 2. pp. 778-783.
@article{89e15257efe14e96a4a02c4016706f83,
title = "Low plasma levels of the soluble receptor for advanced glycation end products in HIV-infected patients with subclinical carotid atherosclerosis receiving combined antiretroviral therapy",
abstract = "Objective: Combined antiretroviral therapy (cART) has significantly improved the survival rate and quality of life for HIV-infected subjects, but it contributes to the development of metabolic complications including coronary artery disease (CAD). Recent studies have reported that high plasma levels of the soluble receptor for advanced glycation end products (sRAGE) were associated with a lower incidence of CAD in non-HIV infected patients. However, there has been no report of an association of sRAGE and subclinical carotid atherosclerosis in HIV-infected patients receiving cART. Methods: We examined the association of circulating sRAGE in HIV-infected patients with carotid intima-media thickness (IMT) and other metabolic variables. We prospectively enrolled 76 HIV-infected patients receiving cART for ≥6 months. Results: sRAGE had a significantly negative correlation with body mass index (r= -0.324, p= 0.005), waist-to-hip ratio (r= -0.335, p= 0.003), systolic blood pressure (BP) (r= -0.359, p= 0.002), diastolic BP (r= -0.343, p= 0.004), total cholesterol (r= -0.240, p= 0.037), low-density lipoprotein-cholesterol (r= -0.284, p= 0.024), log(homeostasis model assessment of insulin resistance [HOMA-IR]) (r= -0.380, p= 0.002) and carotid IMT including max-IMT and mean-IMT (r= -0.358, p= 0.001 and r= -0.329, p= 0.004, respectively). By the use of multiple stepwise regression analyses, systolic BP (p= 0.001) and log[HOMA-IR] (p= 0.001) remained significant independently. Conclusions: These results suggest that sRAGE may have a protective effect against subclinical atherosclerosis by preventing inflammatory responses mediated by the activation of cell surface RAGE in HIV-infected patients receiving cART.",
author = "Jeong, {Su Jin} and Kim, {Chang Oh} and Song, {Young Goo} and Baek, {Ji hyeon} and Kim, {Sun Bean} and Jin, {Sung Joon} and Ku, {Nam Su} and Han, {Sang Hoon} and Choi, {Jun Yong} and Lee, {Hyun Chul} and Kim, {June Myung}",
year = "2011",
month = "12",
day = "1",
doi = "10.1016/j.atherosclerosis.2011.08.003",
language = "English",
volume = "219",
pages = "778--783",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

Low plasma levels of the soluble receptor for advanced glycation end products in HIV-infected patients with subclinical carotid atherosclerosis receiving combined antiretroviral therapy. / Jeong, Su Jin; Kim, Chang Oh; Song, Young Goo; Baek, Ji hyeon; Kim, Sun Bean; Jin, Sung Joon; Ku, Nam Su; Han, Sang Hoon; Choi, Jun Yong; Lee, Hyun Chul; Kim, June Myung.

In: Atherosclerosis, Vol. 219, No. 2, 01.12.2011, p. 778-783.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Low plasma levels of the soluble receptor for advanced glycation end products in HIV-infected patients with subclinical carotid atherosclerosis receiving combined antiretroviral therapy

AU - Jeong, Su Jin

AU - Kim, Chang Oh

AU - Song, Young Goo

AU - Baek, Ji hyeon

AU - Kim, Sun Bean

AU - Jin, Sung Joon

AU - Ku, Nam Su

AU - Han, Sang Hoon

AU - Choi, Jun Yong

AU - Lee, Hyun Chul

AU - Kim, June Myung

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Objective: Combined antiretroviral therapy (cART) has significantly improved the survival rate and quality of life for HIV-infected subjects, but it contributes to the development of metabolic complications including coronary artery disease (CAD). Recent studies have reported that high plasma levels of the soluble receptor for advanced glycation end products (sRAGE) were associated with a lower incidence of CAD in non-HIV infected patients. However, there has been no report of an association of sRAGE and subclinical carotid atherosclerosis in HIV-infected patients receiving cART. Methods: We examined the association of circulating sRAGE in HIV-infected patients with carotid intima-media thickness (IMT) and other metabolic variables. We prospectively enrolled 76 HIV-infected patients receiving cART for ≥6 months. Results: sRAGE had a significantly negative correlation with body mass index (r= -0.324, p= 0.005), waist-to-hip ratio (r= -0.335, p= 0.003), systolic blood pressure (BP) (r= -0.359, p= 0.002), diastolic BP (r= -0.343, p= 0.004), total cholesterol (r= -0.240, p= 0.037), low-density lipoprotein-cholesterol (r= -0.284, p= 0.024), log(homeostasis model assessment of insulin resistance [HOMA-IR]) (r= -0.380, p= 0.002) and carotid IMT including max-IMT and mean-IMT (r= -0.358, p= 0.001 and r= -0.329, p= 0.004, respectively). By the use of multiple stepwise regression analyses, systolic BP (p= 0.001) and log[HOMA-IR] (p= 0.001) remained significant independently. Conclusions: These results suggest that sRAGE may have a protective effect against subclinical atherosclerosis by preventing inflammatory responses mediated by the activation of cell surface RAGE in HIV-infected patients receiving cART.

AB - Objective: Combined antiretroviral therapy (cART) has significantly improved the survival rate and quality of life for HIV-infected subjects, but it contributes to the development of metabolic complications including coronary artery disease (CAD). Recent studies have reported that high plasma levels of the soluble receptor for advanced glycation end products (sRAGE) were associated with a lower incidence of CAD in non-HIV infected patients. However, there has been no report of an association of sRAGE and subclinical carotid atherosclerosis in HIV-infected patients receiving cART. Methods: We examined the association of circulating sRAGE in HIV-infected patients with carotid intima-media thickness (IMT) and other metabolic variables. We prospectively enrolled 76 HIV-infected patients receiving cART for ≥6 months. Results: sRAGE had a significantly negative correlation with body mass index (r= -0.324, p= 0.005), waist-to-hip ratio (r= -0.335, p= 0.003), systolic blood pressure (BP) (r= -0.359, p= 0.002), diastolic BP (r= -0.343, p= 0.004), total cholesterol (r= -0.240, p= 0.037), low-density lipoprotein-cholesterol (r= -0.284, p= 0.024), log(homeostasis model assessment of insulin resistance [HOMA-IR]) (r= -0.380, p= 0.002) and carotid IMT including max-IMT and mean-IMT (r= -0.358, p= 0.001 and r= -0.329, p= 0.004, respectively). By the use of multiple stepwise regression analyses, systolic BP (p= 0.001) and log[HOMA-IR] (p= 0.001) remained significant independently. Conclusions: These results suggest that sRAGE may have a protective effect against subclinical atherosclerosis by preventing inflammatory responses mediated by the activation of cell surface RAGE in HIV-infected patients receiving cART.

UR - http://www.scopus.com/inward/record.url?scp=82955247819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955247819&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2011.08.003

DO - 10.1016/j.atherosclerosis.2011.08.003

M3 - Article

C2 - 21872861

AN - SCOPUS:82955247819

VL - 219

SP - 778

EP - 783

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -